Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals (RXRX) under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 3, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $6.2652, with individual trades ranging from $5.96 to $6.70.
• Following the transaction, Borgeson directly owns 7,121,322 shares of Recursion Pharmaceuticals.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission on September 5, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a share sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates